BLB&B Advisors LLC maintained its stake in shares of Pfizer, Inc. (NYSE:PFE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 260,753 shares of the biopharmaceutical company’s stock at the end of the second quarter. Pfizer comprises 1.5% of BLB&B Advisors LLC’s portfolio, making the stock its 19th largest position. BLB&B Advisors LLC’s holdings in Pfizer were worth $8,920,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Asset Planning Services Ltd. raised its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. raised its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. raised its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new stake in shares of Pfizer during the first quarter worth about $121,000. Finally, Cable Hill Partners LLC raised its stake in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares in the last quarter. Institutional investors and hedge funds own 69.94% of the company’s stock.

Shares of Pfizer, Inc. (NYSE:PFE) traded up 0.48% during trading on Friday, hitting $33.39. The company’s stock had a trading volume of 14,393,883 shares. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.18. The company has a market cap of $198.58 billion, a PE ratio of 24.43 and a beta of 1.00. The firm’s 50 day moving average price is $33.25 and its 200-day moving average price is $33.42.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the firm earned $0.64 EPS. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.

ILLEGAL ACTIVITY NOTICE: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/27/pfizer-inc-pfe-stake-held-by-blbb-advisors-llc.html.

A number of brokerages recently issued reports on PFE. Berenberg Bank reissued a “hold” rating and set a $36.00 price target (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Thursday. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Cowen and Company set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Finally, UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $37.61.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 120,014 shares of company stock valued at $4,062,493 over the last three months. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.